Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study.

Acta dermato-venereologica·2026
Same author

Pyoderma gangrenosum is associated with excess incident major atherothrombotic events.

Atherosclerosis·2026
Same author

Mortality, cardiovascular disease, and cancer in coeliac disease and dermatitis herpetiformis: a matched cohort study.

Lancet regional health. Americas·2026
Same author

Second-Generation H1-Antihistamines Do Not Alter Dementia Risk in Type 2 Inflammatory Diseases: A Target Trial Emulation Using Real-World Data.

The journal of allergy and clinical immunology. In practice·2026
Same author

Response to Meisenheimer et al's "Behind the data: Pitfalls and bias in database research".

Journal of the American Academy of Dermatology·2026
Same author

ANCA-associated vasculitis is associated with an increased risk of cardiac and vascular morbidity: results of a large-scale propensity-matched global retrospective cohort study.

Frontiers in immunology·2026
Same journal

Erythematous Nodules and Plaques on the Neck: A Quiz.

Acta dermato-venereologica·2026
Same journal

Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study.

Acta dermato-venereologica·2026
Same journal

Application of IL-17A Inhibitors in Psoriasis Complicated by Multiple Infections - Successful Treatment and Insights from a Case of Psoriasis with HIV and Neurosyphilis.

Acta dermato-venereologica·2026
Same journal

A Systematic Literature Review on Methotrexate Hepatotoxicity in Psoriasis Management: Preconceived Notion or Real Threat?

Acta dermato-venereologica·2026
Same journal

Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.

Acta dermato-venereologica·2026
See all related articles

Related Experiment Video

Updated: Dec 28, 2025

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

877

Drug Development in Pemphigoid Diseases.

Katja Bieber1, Ralf J Ludwig

  • 1Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.

Acta Dermato-Venereologica
|February 11, 2020
PubMed
Summary
This summary is machine-generated.

New drug development pathways for pemphigoid diseases, including hypothesis-driven and omics-based approaches, aim to create effective and safe treatments for these autoimmune skin conditions.

Keywords:
animal autoantibodiesdisease modelsepidermolysis bullosa acquisitatranslational medical researchbullous pemphigoid

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
09:46

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

3.5K

Related Experiment Videos

Last Updated: Dec 28, 2025

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

877
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
09:46

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

3.5K

Area of Science:

  • Immunodermatology
  • Autoimmune Blistering Diseases
  • Drug Discovery and Development

Background:

  • Pemphigoid diseases are autoimmune disorders targeting the dermal-epidermal junction.
  • Autoantibodies against adhesion molecules cause skin and mucous membrane blistering.
  • Current treatments face limitations, highlighting an unmet need for novel therapies.

Purpose of the Study:

  • To review current and emerging drug development strategies for pemphigoid diseases.
  • To explore diverse pathways for creating effective and safe pemphigoid treatments.
  • To discuss the potential for personalized and curative therapies.

Main Methods:

  • Review of hypothesis-driven drug development.
  • Analysis of omics-based drug development strategies.
  • Examination of drug repurposing initiatives.
  • Evaluation of screening-based drug development.
  • Consideration of clinical observation-based development.

Main Results:

  • Multiple drug development pathways are actively being explored for pemphigoid diseases.
  • Pre-clinical studies and early clinical trials are underway.
  • Diverse approaches aim to address the limitations of existing treatments.

Conclusions:

  • Advancements in understanding pemphigoid pathogenesis are driving novel therapeutic strategies.
  • A combination of approaches may lead to personalized and potentially curative treatments.
  • Continued research is crucial for addressing the unmet medical needs in pemphigoid diseases.